Galmed keeps Nasdaq listing after bid-price fix

Galmed Pharmaceuticals has cured its Nasdaq minimum bid price deficiency, keeping its ordinary shares listed on The Nasdaq Stock Market.

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. (GLMD) reports that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company’s ordinary shares will continue to be listed and traded on The Nasdaq Stock Market after maintaining a closing bid price of at least $1.00 per share for 10 consecutive trading days.

Galmed had previously been notified on January 29, 2026 of a bid-price deficiency and went through an initial and an additional 180-day compliance period before achieving the required trading performance between August 20, 2026 and September 2, 2026. This matter is now closed, and the report is incorporated by reference into the company’s effective Form S-8 and Form F-3 registration statements.

Positive

• Galmed has regained compliance with Nasdaq Listing Rule 5550(a)(2), ensuring its ordinary shares remain listed and traded on The Nasdaq Stock Market.

Negative

• None.

Key Figures

Minimum bid price threshold: $1.00 per share Consecutive trading days at or above threshold: 10 trading days Initial compliance period length: 180 calendar days +3 more

6 metrics

Minimum bid price threshold $1.00 per share Required closing bid price under Nasdaq Listing Rule 5550(a)(2)

Consecutive trading days at or above threshold 10 trading days From August 20, 2026 through September 2, 2026, used to regain compliance

Initial compliance period length 180 calendar days First deadline to regain minimum bid price compliance, ending July 28, 2026

Additional compliance period length 180 calendar days Second period granted after the initial 180-day period expired without compliance

Deficiency notice date January 29, 2026 Date Nasdaq notified Galmed of failure to maintain $1.00 bid price for 30 days

Compliance confirmation date September 3, 2026 Date Nasdaq staff notified Galmed it had regained bid price compliance

Key Terms

minimum bid price requirement, Nasdaq Listing Rule 5550(a)(2), Form 6-K, Registration Statements on Form S-8, +1 more

5 terms

minimum bid price requirement market

"regained compliance with the minimum bid price requirement set forth"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

Nasdaq Listing Rule 5550(a)(2) regulatory

"compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)"

Form 6-K regulatory

"This Form 6-K is incorporated by reference into the Company’s Registration Statements"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

Registration Statements on Form S-8 regulatory

"incorporated by reference into the Company’s Registration Statements on Form S-8"

Registration Statement on Form F-3 regulatory

"and the Company’s Registration Statement on Form F-3"

A registration statement on Form F-3 is a streamlined filing used by eligible foreign companies to register securities for sale in the U.S., often as a “shelf” that lets them offer shares quickly when market conditions are right. For investors it matters because it signals that the company can raise capital on short notice—potentially increasing liquidity but also the risk of share dilution if new stock is issued—similar to a company keeping a pre-approved credit line ready to use.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Galmed Pharmaceuticals (GLMD) announce regarding its Nasdaq listing?

Galmed announced it has regained compliance with the Nasdaq minimum bid price requirement under Rule 5550(a)(2), and its ordinary shares will continue to be listed and traded on The Nasdaq Stock Market after resolving the prior deficiency.

How did GLMD regain compliance with Nasdaq’s minimum bid price rule?

Galmed regained compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive trading days from August 20, 2026 through September 2, 2026, satisfying Nasdaq Listing Rule 5550(a)(2).

When was Galmed (GLMD) first notified of its Nasdaq bid price deficiency?

Galmed was notified on January 29, 2026 that it had failed to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days, triggering the Nasdaq Listing Rule 5550(a)(2) deficiency process.

How long was the compliance period given to GLMD to fix the bid price issue?

Galmed was initially given a 180-calendar-day compliance period until July 28, 2026, and after not regaining compliance in that period, received an additional 180-calendar-day compliance period to cure the deficiency.

How does this 6-K for GLMD relate to its existing registration statements?

This report is incorporated by reference into Galmed’s Registration Statements on Form S-8 (Nos. 333-206292, 333-227441, 333-284163, 333-290399) and Form F-3 (Nos. 333-272722, 333-283241), updating those offerings with the Nasdaq compliance development.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 06:09 AM EDT Accepted by SEC EDGAR 09/08/2026 - 06:08 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of September 2026

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On September 3, 2026, the Nasdaq Listing Qualifications Staff notified Galmed Pharmaceuticals Ltd. (the “Company”) that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company is now in compliance with all applicable listing standards, and its ordinary shares will continue to be listed and traded on The Nasdaq Stock Market.

The Company was previously notified by Nasdaq on January 29, 2026 that it had failed to maintain a minimum bid price of $1.00 per share for 30 consecutive trading days, as required by Nasdaq Listing Rule 5550(a)(2), and was provided until July 28, 2026 to regain compliance. The Company did not regain compliance during the initial 180-calendar-day compliance period and subsequently received an additional 180-calendar-day compliance period to cure the deficiency.

To regain compliance with the minimum bid price requirement, the Company was required to maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days. From August 20, 2026 through September 2, 2026, the closing bid price of the Company’s ordinary shares was $1.00 per share or greater for 10 consecutive trading days. As a result, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and the matter is now closed.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441, 333-284163 and 333-290399) and the Company’s Registration Statement on Form F-3 (Registration Nos. 333-272722 and 333-283241).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.
Date: September 8, 2026	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer